Other languages Replimune Group, Inc.

Equities

REPL

US76029N1063

Market Closed - Nasdaq Other stock markets 02:00:00 04/05/2024 am IST			5-day change	1st Jan Change
6.95 ^USD	+5.95%		+8.26%	-17.56%

08/04	Replimune Group Provides Interim Results for Skin Cancer Therapy	MT
26/03	Replimune Group, Inc. Announces Management Changes	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Replimune Group Provides Interim Results for Skin Cancer Therapy	08/04
Replimune Group, Inc. Announces Management Changes	26/03
Replimune Group, Inc. Announces CEO Changes, Effective April 1, 2024	26/03
Replimune Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	08/02
Sector Update: Health Care Stocks Ease Late Afternoon	06/12
Sector Update: Health Care	06/12
Replimune Group Shares Slide as Trial of Skin Cancer Treatment Candidate Failed to Meet Primary Endpoints	06/12
Replimune's skin cancer drug fails in late-stage study	05/12
Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers	05/12
Replimune Group Shares Fall After Fiscal Q2 Loss Widens; Company Sees Cash to Fund Operations Into H2 2025	08/11
Replimune Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	07/11
Replimune Group, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	03/23/03
Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors	20/23/20
Insider Sell: Replimune Group	16/23/16
Insider Sell: Replimune Group	16/23/16
Replimune Group, Inc. Appoints Veleka R. Peeples-Dyer to Its Board of Directors	05/23/05
Replimune Group, Inc. Presents RP1 Data from the IGNYTE Anti-PD1 Failure Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology Annual Meeting	03/23/03
Replimune Group's Fiscal Q4 Net Loss Widens; Chief Financial Officer Jean Franchi to Depart	18/23/18
Replimune Group, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	18/23/18
Replimune's Fiscal Q3 Loss Widens; Company Sees Cash Runway to Fund Operations Into Second Half of 2025	09/23/09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Replimune Group, Inc.

Equities

REPL

US76029N1063

Other languages

Filters